Open

Stage IV or Recurrent Non-Small Cell Lung Cancer Study

This is a clinical research study for people with Stage 4 lung cancer or lung cancer that has returned after treatment. In this study, we want to learn if treatment with two study drugs (ramucirumab and pembrolizumab) works better than usual treatment.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

At each visit, you will see a member of the medical and study team to assess your health status and side effects. Your doctor will also order lab tests and imaging as needed to help us learn more about your response to the study treatment.

In-person visits:
1-52

Phone or online visits:
None

Total length of participation:
3 years

Looking for Specific Volunteers

Able to participate:

You have non-small cell lung cancer
You have Stage 4 or recurrent lung cancer
You have previously received chemotherapy
You have previously received immunotherapy

Not eligible if:

You are taking another investigational therapy

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

UNC Rex Cancer Center
2901 Blue Ridge Rd, Raleigh, NC 27607, USA

Additional Study Information

Principal Investigator

Robert Wehbie
UNC Hospitals - Rex

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung)

IRB Number

23-1032

ClinicalTrials.gov

NCT05633602

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.